Titan Pharmaceuticals (NASDAQ:TTNP) and Axcella Health (NASDAQ:AXLA) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, risk, profitability, dividends and earnings.
This is a breakdown of current ratings and price targets for Titan Pharmaceuticals and Axcella Health, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Valuation & Earnings
This table compares Titan Pharmaceuticals and Axcella Health’s revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Titan Pharmaceuticals||$6.62 million||2.86||-$9.02 million||($0.79)||-1.77|
|Axcella Health||N/A||N/A||-$36.07 million||N/A||N/A|
Titan Pharmaceuticals has higher revenue and earnings than Axcella Health.
Insider & Institutional Ownership
5.1% of Titan Pharmaceuticals shares are owned by institutional investors. 6.5% of Titan Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
This table compares Titan Pharmaceuticals and Axcella Health’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Axcella Health beats Titan Pharmaceuticals on 5 of the 9 factors compared between the two stocks.
Titan Pharmaceuticals Company Profile
Titan Pharmaceuticals, Inc., a pharmaceutical company, develops proprietary therapeutics for the treatment of serious medical disorders. It develops products based on ProNeura, a proprietary long-term drug delivery platform that focuses primarily on treatments for chronic diseases. The company offers Probuphine, a product candidate for maintenance treatment of opioid dependence, which maintains a stable, around the clock blood level of the drug buprenorphine in patients for six months following a single treatment. It also develops ProNeura-Ropinirole, an implant to provide delivery of ropinirole, a dopamine agonist for the treatment of Parkinson's disease; and triiodothyronine, an implant for the treatment of hypothyroidism. The company has a collaboration with Nevada Center for Behavioral Health to evaluate a medication-assisted treatment program utilizing Probuphine (buprenorphine) implant for Opioid Use Disorder (OUD) patients. Titan Pharmaceuticals, Inc. was founded in 1992 and is based in South San Francisco, California.
Axcella Health Company Profile
There is no company description available for Axcella Health Inc.
Receive News & Ratings for Titan Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Titan Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.